{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:21:09Z","timestamp":1790000469277,"version":"4.0.1"},"reference-count":181,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    As nucleic acid vaccine technology continues to advance, modern adjuvants are being engineered to quantitatively and qualitatively shape immune responses. Since their development in the early 1990\u2019s, nucleic acid approaches have garnered significant attention, and numerous platform technologies have been developed both to improve delivery as well as immunogenicity. These advances were highlighted during the COVID-19 pandemic, with the approval of both mRNA-LNP and DNA vaccines for SARS-CoV-2. Early clinical trials with DNA antigens alone displayed suboptimal immunogenicity, supporting interest in adjuvant molecules. Molecular adjuvants, nucleic acid-encoded cytokines, chemokines, and enzymes, among others, are used to enhance and direct nucleic acid antigen-induced immunity\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Additionally, mRNA-LNP vaccines, and more recently DNA-LNP vaccines, have demonstrated robust immunogenicity with intrinsic adjuvant activity based on the delivery mode. This review summarizes the molecular adjuvant landscape and highlights recent findings in the context of nucleic acid vaccines.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1646800","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:22:21Z","timestamp":1759148541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in molecular adjuvants for nucleic acid vaccines"],"prefix":"10.3389","volume":"16","author":[{"given":"Casey E.","family":"Hojecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Tursi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Livingston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony N.","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3020320","article-title":"Vaccine adjuvants: From 1920 to 2015 and beyond","volume":"3","author":"Di Pasquale","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.038943-0","article-title":"Alum adjuvant: Some of the tricks of the oldest adjuvant","volume":"61","author":"Kool","year":"2012","journal-title":"J Med Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10663","article-title":"Vaccine adjuvants for infectious disease in the clinic","volume":"9","author":"Goetz","year":"2024","journal-title":"Bioeng Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Sci (1979)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.9.4156","article-title":"Gene inoculation generates immune responses against human immunodeficiency virus type 1","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2432","article-title":"DNA vaccines: Ready for prime time","volume":"9","author":"Kutzler","year":"2008","journal-title":"Nat Rev Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1138609","article-title":"Adenosine deaminase augments SARS-CoV-2 specific cellular and humoral responses in aged mouse models of immunization and challenge","volume":"14","author":"Gary","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2200056","article-title":"Improved durability to SARS-CoV-2 vaccine immunity following coimmunization with molecular adjuvant adenosine deaminase-1","volume":"209","author":"Cusimano","year":"2022","journal-title":"J Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.03.047","article-title":"Adenosine deaminase-1 enhances germinal center formation and functional antibody responses to HIV-1 Envelope DNA and protein vaccines","volume":"38","author":"Gary","year":"2020","journal-title":"Vaccine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0684.2005.00124.x","article-title":"SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques","volume":"34","author":"Boyer","year":"2005","journal-title":"J Med Primatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.025","article-title":"Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo","volume":"20","author":"Kraynyak","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7020042","article-title":"Designed DNA-encoded IL-36 gamma acts as a potent molecular adjuvant enhancing Zika synthetic DNA vaccine-induced immunity and protection in a lethal challenge model","volume":"12","author":"Louis","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.01.023","article-title":"CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine","volume":"38","author":"Gary","year":"2020","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22574","article-title":"Generation of antigen-specific immunity following systemic immunization with DNA vaccine encoding CCL25 chemokine immunoadjuvant","volume":"8","author":"Kathuria","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.10.095","article-title":"Systemic immunization with CCL27\/CTACK modulates immune responses at mucosal sites in mice and macaques","volume":"28","author":"Kraynyak","year":"2010","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/gt.2009.112","article-title":"Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo","volume":"17","author":"Kutzler","year":"2010","journal-title":"Gene Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/mi.2015.31","article-title":"Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge","volume":"9","author":"Kutzler","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029231","article-title":"Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and\/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults","volume":"7","author":"Kalams","year":"2012","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.137079","article-title":"Robust antibody and cellular responses induced by DNA-only vaccination for HIV","volume":"5","author":"de Rosa","year":"2020","journal-title":"JCI Insight"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1089\/088922203769232610","article-title":"Codon usage optimization of HIV type 1 subtype C gag, pol, env, and nef genes: In vitro expression and immune responses in DNA-vaccinated mice","volume":"19","author":"Gao","year":"2003","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.17.9174-9189.2004","article-title":"Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization","volume":"78","author":"Ramakrishna","year":"2004","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302184","article-title":"Codon optimization and mRNA amplification effectively enhances the immunogenecity of the hepatitis C virus nonstructural 3\/4A gene","volume":"11","author":"Frelin","year":"2004","journal-title":"Gene Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16505-0","article-title":"Immunogenicity of a DNA vaccine candidate for COVID-19","volume":"11","author":"Smith","year":"2020","journal-title":"Nat Commun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiac016","article-title":"SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial","volume":"225","author":"Kraynyak","year":"2022","journal-title":"J Infect Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2448405","DOI":"10.1080\/21645515.2024.2448405","article-title":"Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial","volume":"21","author":"Jia","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2020.01.006","article-title":"DNA vaccines: prime time is now","volume":"65","author":"Gary","year":"2020","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1751-7915.70053","article-title":"New insights for the development of efficient DNA vaccines","volume":"17","author":"Berger","year":"2024","journal-title":"Microb Biotechnol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332939","article-title":"The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457327","article-title":"DNA and RNA vaccines against tuberculosis: a scoping review of human and animal studies","volume":"15","author":"Kazakova","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.04.008","article-title":"DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets","volume":"33","author":"Bhojnagarwala","year":"2025","journal-title":"Mol Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14081698","article-title":"Efficient delivery of DNA using lipid nanoparticles","volume":"14","author":"Cui","year":"2022","journal-title":"Pharmaceutics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31993-y","article-title":"Multi-step screening of DNA\/lipid nanoparticles and co-delivery with siRNA to enhance and prolong gene expression","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1039\/d2bm00168c","article-title":"In vivo delivery of plasmid DNA by lipid nanoparticles: the influence of ionizable cationic lipids on organ-selective gene expression","author":"Algarni","year":"2022","journal-title":"Biomater Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2023.101169","article-title":"Lipid nanoparticle-encapsulated DNA vaccine robustly induce superior immune responses to the mRNA vaccine in Syrian hamsters","volume":"32","author":"Liao","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44830-1","article-title":"Nanoparticle-based DNA vaccine protects against SARS-CoV-2 variants in female preclinical models","volume":"15","author":"Guimaraes","year":"2024","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102035","article-title":"Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity","volume":"6","author":"Tursi","year":"2025","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adm8451","article-title":"Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70","volume":"16","author":"Brook","year":"2024","journal-title":"Sci Transl Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","article-title":"Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses","volume":"119","author":"McMahon","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV preF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"New Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-1196","article-title":"Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines","volume":"14","author":"Berraondo","year":"2024","journal-title":"Cancer Discov"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.581812","article-title":"IL-12 DNA displays efficient adjuvant effects improving immunogenicity of Ag85A in DNA prime\/MVA boost immunizations","volume":"10","author":"Morelli","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads1328","article-title":"An Il12 mRNA-LNP adjuvant enhances mRNA vaccine\u2013induced CD8 T cell responses","volume":"10","author":"Aunins","year":"2025","journal-title":"Sci Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.vetmic.2019.01.008","article-title":"Adjuvant effects of interleukin-2 co-expression with VP60 in an oral vaccine delivered by attenuated Salmonella typhimurium against rabbit hemorrhagic disease","volume":"230","author":"Deng","year":"2019","journal-title":"Vet Microbiol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/v11050476","article-title":"Co-expression of chicken il-2 and il-7 enhances the immunogenicity and protective efficacy of a vp2-expressing dna vaccine against ibdv in chickens","volume":"11","author":"Huo","year":"2019","journal-title":"Viruses"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2020.103615","article-title":"Interleukin-2 (IL-2) of flounder (Paralichthys olivaceus) as immune adjuvant enhance the immune effects of E. tarda subunit vaccine OmpV against Edwardsiellosis","volume":"106","author":"Tang","year":"2020","journal-title":"Dev Comp Immunol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01322-23","article-title":"Co-administration of chicken IL-2 alleviates clinical signs and replication of the ILTV chicken embryo origin vaccine by pre-activating natural killer cells and cytotoxic T lymphocytes","volume":"97","author":"Hao","year":"2023","journal-title":"J Virol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0327","article-title":"Multicomponent plasmid protects mice from spontaneous autoimmune diabetes","volume":"71","author":"Pagni","year":"2022","journal-title":"Diabetes"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123039","article-title":"Lipid nanoparticles encapsulating both adjuvant and antigen mRNA improve influenza immune cross-protection in mice","volume":"317","author":"Wei","year":"2025","journal-title":"Biomaterials"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2023.103204","article-title":"Immune synergistic mechanism of recombinant plasmid adjuvant containing chicken IL-4 and IL-2 fusion genes on chicken coccidia live vaccine","volume":"103","author":"Tan","year":"2024","journal-title":"Poult Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10030461","article-title":"Cytokine adjuvants IL-7 and IL-15 improve humoral responses of a SHIV lentiDNA vaccine in animal models","volume":"10","author":"Leroy","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12985-024-02604-7","article-title":"Augmented immunogenicity of the HPV16 DNA vaccine via dual adjuvant approach: integration of CpG ODN into plasmid backbone and co-administration with IL-28B gene adjuvant","volume":"22","author":"Zhou","year":"2025","journal-title":"Virol J"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2022.109474","article-title":"Protection against genotype VII Newcastle disease virus challenge by a minicircle DNA vaccine coexpressing F protein and chicken IL-18 adjuvant","volume":"270","author":"Wang","year":"2022","journal-title":"Vet Microbiol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106370","article-title":"IL-18 immunoadjuvanted xenogeneic canine MMP-7 DNA vaccine overcomes immune tolerance and supresses the growth of murine mammary tumor","volume":"82","author":"Yadav","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-020-04900-3","article-title":"Protective cellular and mucosal immune responses following nasal administration of a whole gamma-irradiated influenza A (subtype H1N1) vaccine adjuvanted with interleukin-28B in a mouse model","volume":"166","author":"Sabbaghi","year":"2021","journal-title":"Arch Virol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-024-10590-y","article-title":"Development of a genotype-matched Newcastle disease DNA vaccine candidate adjuvanted with IL-28b for the control of targeted velogenic strains of Newcastle disease virus in Africa","volume":"49","author":"Amoia","year":"2025","journal-title":"Vet Res Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.130660","article-title":"pGM-CSF as an adjuvant in DNA vaccination against SARS-CoV-2","volume":"264","author":"Liu","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100693","article-title":"Mucosal chemokine adjuvant enhances synDNA vaccine-mediated responses to SARS-CoV-2 and provides heterologous protection in vivo","volume":"3","author":"Gary","year":"2022","journal-title":"Cell Rep Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127231","article-title":"DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo","volume":"59","author":"Liaw","year":"2025","journal-title":"Vaccine"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.dci.2019.103492","article-title":"The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus)","volume":"103","author":"Xu","year":"2020","journal-title":"Dev Comp Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-022-2231-8","article-title":"DNA vaccine dual-expressing viral hemorrhagic septicemia virus glycoprotein and C-C motif chemokine ligand 19 induces the expression of immune-related genes in zebrafish (Danio rerio)","volume":"60","author":"Kim","year":"2022","journal-title":"J Microbiol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13010010","article-title":"Intranasal immunization with DNA vaccine HA-CCL19\/polyethylenimine\/chitosan composite provides immune protection against H7N9 infection","volume":"13","author":"Xiang","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.5A0818-333R","article-title":"Dendritic cell-targeted CD40 DNA vaccine suppresses Th17 and ameliorates progression of experimental autoimmune glomerulonephritis","volume":"105","author":"Li","year":"2019","journal-title":"J Leukoc Biol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.785349","article-title":"DNA based vaccine expressing SARS-CoV-2 spike-CD40L fusion protein confers protection against challenge in a Syrian hamster model","volume":"12","author":"Tamming","year":"2022","journal-title":"Front Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00926-9","article-title":"Duck CD40L as an adjuvant enhances systemic immune responses of avian flavivirus DNA vaccine","volume":"9","author":"Huang","year":"2024","journal-title":"NPJ Vaccines"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.071","article-title":"A plasmid encoding the extracellular domain of CD40 ligand and Montanide\u2122 GEL01 as adjuvants enhance the immunogenicity and the protection induced by a DNA vaccine against BoHV-1","volume":"39","author":"Kornuta","year":"2021","journal-title":"Vaccine"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881753","article-title":"Characterization of Co-Stimulatory Ligand CD80\/86 and Its Effect as a Molecular Adjuvant on DNA Vaccine Against Vibrio Anguillarum in Flounder (Paralichthys olivaceus)","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-019-1156-2","article-title":"A candidate DNA vaccine encoding a fusion protein of porcine complement C3d-P28 and ORF2 of porcine circovirus type 2 induces cross-protective immunity against PCV2b and PCV2d in pigs","volume":"16","author":"Hou","year":"2019","journal-title":"Virol J"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-023-01082-6","article-title":"Enhancing the immunogenicity of lipid-nanoparticle mRNA vaccines by adjuvanting the ionizable lipid and the mRNA","volume":"9","author":"Li","year":"2023","journal-title":"Nat BioMed Eng"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1084\/jem.170.3.827","article-title":"Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes","volume":"170","author":"Kobayashi","year":"1989","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1126\/science.7904381","article-title":"The adjuvant effect of interleukin-12 in a vaccine against Leishmania major","volume":"263","author":"Afonso","year":"1994","journal-title":"Sci (1979)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.2.816","article-title":"In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen","volume":"158","author":"Kim","year":"1997","journal-title":"J Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"Kalams","year":"2013","journal-title":"J Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000830","article-title":"The safety and immunogenicity of an interleukin-12-enhanced multiantigen DNA vaccine delivered by electroporation for the treatment of HIV-1 infection","volume":"71","author":"Jacobson","year":"2016","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines8040741","article-title":"Intramuscular and intradermal electroporation of hiv-1 pennvax-gp\u00ae DNA vaccine and IL-12 is safe, tolerable, acceptable in healthy adults","volume":"8","author":"Edupuganti","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-22-0217","article-title":"Phase I trial of a therapeutic DNA vaccine for preventing hepatocellular carcinoma from chronic hepatitis C virus (HCV) infection","volume":"16","author":"Jacobson","year":"2023","journal-title":"Cancer Prev Res (Phila)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.2004","article-title":"Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma","volume":"40","author":"Reardon","year":"2022","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.33696\/immunology.6.188","article-title":"Personalized neoantigen DNA cancer vaccines: current status and future perspectives","volume":"6","author":"Viborg","year":"2024","journal-title":"J Cell Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.201","article-title":"Systemic production of IL-12 by naked DNA mediated gene transfer: Toxicity and attenuation of transgene expression in vivo","volume":"3","author":"Lui","year":"2001","journal-title":"J Gene Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-\u03b3 production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03278-y","article-title":"SARS-CoV-2-specific plasma cells are not durably established in the bone marrow long-lived compartment after mRNA vaccination","volume":"31","author":"Nguyen","year":"2024","journal-title":"Nat Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.11.4240","article-title":"Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine","volume":"86","author":"Nunberg","year":"1989","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2005.18.649","article-title":"Adjuvant action of murine IL-2\/Ig plasmid after intramuscular immunization with Indian HIV-1 subtype C recombinant env.gp 120 construct","volume":"18","author":"Aggarwal","year":"2005","journal-title":"Viral Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00005537-200503000-00002","article-title":"Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: From bench top to bedside","volume":"115","author":"O\u2019Malley","year":"2005","journal-title":"Laryngoscope"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.8578","article-title":"Phase I trial of IL-2 plasmid DNA with electroporation in metastatic melanoma","volume":"25","author":"Richards","year":"2007","journal-title":"J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/BF02975371","article-title":"Vaccination with an ovalbumin\/interleukin-4 fusion DNA efficiently induces Th2 cell-mediated immune responses in an ovalbumin-specific manner","volume":"21","author":"Lim","year":"1998","journal-title":"Arch Pharm Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0708","article-title":"Engineered fusokine GIFT4 licenses the ability of B cells to trigger a tumoricidal T-cell response","volume":"74","author":"Deng","year":"2014","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.157.5.2103","article-title":"IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice","volume":"157","author":"Khan","year":"1996","journal-title":"J Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.1.112","article-title":"Coimmunization with an optimized IL-15 plasmid results in enhanced function and longevity of CD8 T cells that are partially independent of CD4 T cell help","volume":"175","author":"Kutzler","year":"2005","journal-title":"J Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1004621","article-title":"Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-Herpes simplex virus immunity","volume":"78","author":"Toka","year":"2005","journal-title":"J Leukoc Biol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.646159","article-title":"Development of stable chimeric IL-15 for trans-presentation by the antigen presenting cells","volume":"12","author":"Patidar","year":"2021","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.507","article-title":"IL-15 regulates CD8+ T cell contraction during primary infection","volume":"176","author":"Yajima","year":"2006","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab014","article-title":"Next-generation cytokines for cancer immunotherapy","volume":"4","author":"Xue","year":"2021","journal-title":"Antib Ther"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0019","article-title":"An antibody fusion protein for cancer immunotherapy mimicking IL-15 trans-presentation at the tumor site","volume":"11","author":"Kermer","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2022.122059","article-title":"Enhanced half-life and antitumor activity of interleukin-15 through genetic fusion of a serum albumin-specific protein binder","volume":"625","author":"Kim","year":"2022","journal-title":"Int J Pharm"},{"key":"B105","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/378088a0","article-title":"Cloning of a new cytokine that induces IFN-\u03b3 production by T cells","volume":"378","author":"Okamura","year":"1995","journal-title":"Nature"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200636465","article-title":"IL-18 time-dependently modulates Th1\/Th2 cytokine production by ligand-activated NKT cells","volume":"37","author":"Uchida","year":"2007","journal-title":"Eur J Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.75.18.8424-8433.2001","article-title":"Feline leukemia virus DNA vaccine efficacy is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors","volume":"75","author":"Hanlon","year":"2001","journal-title":"J Virol"},{"key":"B108","unstructured":"Intradermal vaccination of MUC1 transgenic mice with MUC1\/IL-18 plasmid DNA inhibits experimental pulmonary metastases\n          \n          \n            \n              Shi\n              F\n            \n            \n              Gunn\n              GR\n            \n            \n              Snyder\n              L\n            \n            \n              Goletz\n              TJ\n            \n          \n          17292519\n          \n          2004"},{"key":"B109","unstructured":"IL-18 enhances the immune response to a PSA DNA vaccine in Balb\/c mice\n          \n          \n            \n              Marshall\n              D\n            \n            \n              Mateo\n              LS\n            \n            \n              Rudnick\n              K\n            \n            \n              McCarthy\n              S\n            \n            \n              Snyder\n              L\n            \n          \n          \n          2004"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.014","article-title":"A MUC1\/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice","volume":"24","author":"Snyder","year":"2006","journal-title":"Vaccine"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-\u03bb), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J Virol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-11-190520","article-title":"Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity","volume":"113","author":"Morrow","year":"2009","journal-title":"Blood"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.118","article-title":"IL-28B\/IFN\u03bb-3 drives granzyme B loading and significantly increases CTL killing activity in macaques","volume":"18","author":"Morrow","year":"2010","journal-title":"Mol Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050484","article-title":"Local Sustained GM-CSF Delivery by Genetically Engineered Encapsulated Cells Enhanced Both Cellular and Humoral SARS-CoV-2 Spike-Specific Immune Response in an Experimental Murine Spike DNA Vaccination Model","volume":"9","author":"Vernet","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/BF01973602","article-title":"Potential role of granulocyte-macrophage colony-stimulating factor as vaccine adjuvant","volume":"13","author":"Jones","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.196","article-title":"Phase I\/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma","volume":"16","author":"Perales","year":"2008","journal-title":"Mol Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br J Cancer"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0945","article-title":"Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer","volume":"26","author":"Kyriakopoulos","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0090413","article-title":"Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities","volume":"9","author":"Luo","year":"2014","journal-title":"PloS One"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/S11033-014-3470-5\/FIGURES\/5","article-title":"Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant","volume":"41","author":"Hartoonian","year":"2014","journal-title":"Mol Biol Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2018.07.003","article-title":"Chemokine CCL20 plasmid improves protective efficacy of the Montanide ISA\u2122 206 adjuvanted foot-and-mouth disease vaccine in mice model","volume":"36","author":"Jayeshbhai","year":"2018","journal-title":"Vaccine"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.1901184","article-title":"Chemokine-adjuvanted plasmid DNA induces homing of antigen-specific and non\u2013antigen-specific B and T cells to the intestinal and genital mucosae","volume":"204","author":"Aldon","year":"2020","journal-title":"J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1292059\/BIBTEX","article-title":"A SARS-CoV-2 RBD vaccine fused to the chemokine MIP-3\u03b1 elicits sustained murine antibody responses over 12 months and enhanced lung T-cell responses","volume":"15","author":"Gordy","year":"2024","journal-title":"Front Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000542","article-title":"Brief communication: combination of an MIP3\u03b1-antigen fusion therapeutic DNA vaccine with treatments of IFN\u03b1 and 5-aza-2\u2032Deoxycytidine enhances activated effector CD8+ T cells expressing CD11c in the B16F10 melanoma model","volume":"48","author":"Fessler","year":"2025","journal-title":"J Immunotherapy"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S40425-016-0189-Y\/FIGURES\/6","article-title":"Fusion of the dendritic cell-targeting chemokine mip3\u03b1 to melanoma antigen gp100 in a therapeutic dna vaccine significantly enhances immunogenicity and survival in a mouse melanoma model","volume":"4","author":"Gordy","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000212","article-title":"Anti-IL-10-mediated enhancement of antitumor efficacy of a dendritic cell-targeting MIP3\u03b1-gp100 vaccine in the B16F10 mouse melanoma model is dependent on type I interferons","volume":"41","author":"Gordy","year":"2018","journal-title":"J Immunotherapy"},{"key":"B127","unstructured":"The lymphoid chemokine CCL19 (ELC) promotes T cell proliferation in vitro and mediates T cell migration when expressed in a recombinant vaccinia virus: A strategy for local tumor vaccine delivery\n          \n          \n            \n              Flanagan\n              K\n            \n            \n              H\u00f6rig\n              H\n            \n            \n              Kaufman\n              H\n            \n          \n          \n          2004"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-007-0228-4","article-title":"Evolution of CC chemokines in teleost fish: A case study in gene duplication and implications for immune diversity","volume":"59","author":"Peatman","year":"2007","journal-title":"Immunogenetics"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2024.101325","article-title":"Lipid nanoparticle encapsulation of a Delta spike-CD40L DNA vaccine improves effectiveness against Omicron challenge in Syrian hamsters","volume":"32","author":"Tamming","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00283-24","article-title":"Lipid nanoparticle-encapsulated DNA vaccine confers protection against swine and human-origin H1N1 influenza viruses","volume":"9","author":"Nguyen","year":"2024","journal-title":"mSphere"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060666","article-title":"Lipid nanoparticles outperform electroporation in delivering therapeutic HPV DNA vaccines","volume":"12","author":"Li","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102261","article-title":"Boosting DNA vaccine power by lipid nanoparticles surface engineered with amphiphilic bioresorbable copolymer","volume":"35","author":"Yang","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1020134","article-title":"DNA lipid nanoparticle vaccine targeting outer surface protein C affords protection against homologous Borrelia burgdorferi needle challenge in mice","volume":"14","author":"Pfeifle","year":"2023","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.03.018","article-title":"Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy","volume":"369","author":"Qin","year":"2024","journal-title":"J Controlled Release"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02211-8","article-title":"Lipid nanoparticles deliver DNA-encoded biologics and induce potent protective immunity","volume":"24","author":"Chai","year":"2025","journal-title":"Mol Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.12.5777","article-title":"Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization","volume":"159","author":"Mendoza","year":"1997","journal-title":"J Immunol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz137","article-title":"A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model","volume":"220","author":"Hashem","year":"2019","journal-title":"J Infect Dis"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00080-06","article-title":"Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks","volume":"13","author":"Gares","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Sci (1979)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.4.1831","article-title":"Role of CD80 (B7.1) and CD86 (B7.2) in the immune response to an intracellular pathogen","volume":"160","author":"Subauste","year":"1998","journal-title":"J Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0797-641","article-title":"Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes","volume":"15","author":"Kirn","year":"1997","journal-title":"Nat Biotechnol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.158.10.4591","article-title":"Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines","volume":"158","author":"Iwasaki","year":"1997","journal-title":"J Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00327","article-title":"Adjuvant screen identifies synthetic DNA-encoding Flt3L and CD80 immunotherapeutics as candidates for enhancing anti-tumor T cell responses","volume":"11","author":"Thorne","year":"2020","journal-title":"Front Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.198.supp.225.15","article-title":"Adenosine DeAminase (ADA) as an adjuvant molecule for human HIV-1 vaccine","volume":"198","author":"Tardif","year":"2017","journal-title":"J Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5247.348","article-title":"C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity","volume":"271","author":"Dempsey","year":"1996","journal-title":"Sci (1979)"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"B147","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.011","article-title":"Pro-inflammatory concerns with lipid nanoparticles","volume":"30","author":"Moghimi","year":"2022","journal-title":"Mol Ther"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-\u03baB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101596","article-title":"A single-dose intramuscular immunization of pigs with lipid nanoparticle DNA vaccines based on the hemagglutinin antigen confers complete protection against challenge infection with the homologous influenza virus strain","volume":"11","author":"Nguyen","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J Mol Biol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635986","article-title":"On DNA vaccines and prolonged expression of immunogens","volume":"36","author":"Hanke","year":"2006","journal-title":"Eur J Immunol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.addr.2020.06.019","article-title":"Controlling timing and location in vaccines","volume":"158","author":"Irvine","year":"2020","journal-title":"Adv Drug Delivery Rev"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010071","article-title":"DNA vaccines: their formulations, engineering and delivery","volume":"12","author":"Kozak","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES7020037","article-title":"A comparison of plasmid DNA and mRNA as vaccine technologies","volume":"7","author":"Liu","year":"2019","journal-title":"Vaccines"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2281733","article-title":"Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models","volume":"19","author":"Andrade","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0288-3","article-title":"RIG-I-like receptors: their regulation and roles in RNA sensing","volume":"20","author":"Rehwinkel","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.02.056","article-title":"RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade","volume":"41","author":"Heidegger","year":"2019","journal-title":"EBioMedicine"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2018.11.041","article-title":"TcVac1 vaccine delivery by intradermal electroporation enhances vaccine induced immune protection against Trypanosoma cruzi infection in mice","volume":"37","author":"Hegazy-Hassan","year":"2019","journal-title":"Vaccine"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/J.VACCINE.2017.10.044","article-title":"Dissecting antigen processing and presentation routes in dermal vaccination strategies","volume":"35","author":"Platteel","year":"2017","journal-title":"Vaccine"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12929-024-01080-Z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J Biomed Sci"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3109\/00016489.2011.576429","article-title":"A single nasal dose of CCL20 chemokine induces dendritic cell recruitment and enhances nontypable Haemophilus influenzae-specific immune responses in the nasal mucosa","volume":"131","author":"Kodama","year":"2011","journal-title":"Acta Otolaryngol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES11081333","article-title":"Efficiency of chitosan nanocarriers in vaccinology for mucosal immunization","volume":"11","author":"Gaglio","year":"2023","journal-title":"Vaccines"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3390\/VACCINES12020191","article-title":"Vaccine strategies to elicit mucosal immunity","volume":"12","author":"Song","year":"2024","journal-title":"Vaccines"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/NRI1777;KWRD=BIOMEDICINE","article-title":"Mucosal vaccines: The promise and the challenge","volume":"6","author":"Neutra","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1021\/ACS.JMEDCHEM.2C00808\/SUPPL_FILE\/JM2C00808_SI_002.CSV","article-title":"Covalently conjugated NOD2\/TLR7 agonists are potent and versatile immune potentiators","volume":"65","author":"Guzelj","year":"2022","journal-title":"J Med Chem"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1111\/IMM.13526","article-title":"Vaccines, adjuvants and key factors for mucosal immune response","volume":"167","author":"Correa","year":"2022","journal-title":"Immunology"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1111\/J.1574-695X.2002.TB00551.X","article-title":"Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA","volume":"32","author":"McCluskie","year":"2002","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-415847-4.00062-8","article-title":"Use of CpG oligonucleotides as mucosal adjuvants","author":"Gursel","year":"2015","journal-title":"Mucosal Immunology: Fourth Edition"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(93)90039-Z","article-title":"Cholera toxin and cholera B subunit as oral\u2014mucosal adjuvant and antigen vector systems","volume":"11","author":"Holmgren","year":"1993","journal-title":"Vaccine"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0139368","article-title":"Nasal administration of cholera toxin as a mucosal adjuvant damages the olfactory system in mice","volume":"10","author":"Fukuyama","year":"2015","journal-title":"PloS One"},{"key":"B177","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s43586-025-00383-1","article-title":"Computational protein design","volume":"5","author":"Albanese","year":"2025","journal-title":"Nat Rev Methods Primers"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107087","article-title":"Designing a bioadjuvant candidate vaccine targeting infectious bursal disease virus (IBDV) using viral VP2 fusion and chicken IL-2 antigenic epitope: A bioinformatics approach","volume":"163","author":"Soleymani","year":"2023","journal-title":"Comput Biol Med"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0830-7","article-title":"De novo design of potent and selective mimics of IL-2 and IL-15","volume":"565","author":"Silva","year":"2019","journal-title":"Nature"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1002\/ange.202301059","article-title":"Computer-aided discovery of potent broad-spectrum vaccine adjuvants","volume":"135","author":"Ma","year":"2023","journal-title":"Angewandte Chemie"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.105057","article-title":"An overview of progress from empirical to rational design in modern vaccine development, with an emphasis on computational tools and immunoinformatics approaches","volume":"140","author":"Soleymani","year":"2022","journal-title":"Comput Biol Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1646800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:22:26Z","timestamp":1759148546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1646800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":181,"alternative-id":["10.3389\/fimmu.2025.1646800"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1646800","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1646800"}}